Discover how the cutting-edge imaging technique, Technetium-99m-Pyrophosphate SPECT/CT, is revolutionizing the monitoring of treatment progress in patients battling the rare and challenging Hereditary Transthyretin Amyloid Cardiomyopathy.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
Yu et al., J Am Heart Assoc 2024
DOI: 10.1161/JAHA.123.030512
Oh, What a “Radiant” Idea!
So, in the latest episode of “How to Track an Incurable Disease,” researchers have stumbled upon a glowing idea. They’ve decided to play around with bone scintigraphy to see if it can double as a spy gadget for monitoring the elusive hereditary transthyretin amyloid cardiomyopathy (hATTR-CM). Because, you know, when you’re dealing with a progressive and fatal disease, why not add a bit of radioactive flair?
Enter the star of the show, eplontersen, which sounds more like an alien overlord than a therapy. Patients in the NEURO-TTRansform trial were given this potential wonder drug, and then—get this—were scanned with technetium-99m-pyrophosphate, which is not a secret code, but a radioactive tracer that lights up their insides like a Christmas tree. The control group, on the other hand, got to sit back and enjoy the show without any of the fancy drugs or glow-in-the-dark experiences.
After a median follow-up of 544 days (because who needs round numbers), the eplontersen group’s heart and lung ratio dropped from 3.774 to 2.979 (P=0.028). In layman’s terms, their internal light show dimmed significantly, suggesting that eplontersen might be doing something right. The control group? Not so much change in their internal festivities (4.079 to 3.915, P=0.237).
And the grand finale: a whopping -20.7% reduction in the heart and lung ratio for the eplontersen group compared to a mere -3.4% for the control group (P=0.007). Cue the applause for eplontersen and its potential to turn down the lights on hATTR-CM.
So, what have we learned? That technetium-99m-pyrophosphate SPECT/CT might just be the next best thing since sliced bread for monitoring this heart-wrenching condition. And eplontersen? It could be the guest of honor at the hATTR-CM treatment party. Stay tuned for the next thrilling installment!